Building on previous work (Jinek et al., 2013), we report a simple and robust system to achieve high fidelity and high efficiency (30% of homologous recombination) genome engineering by homology-directed repair pathway in human cells using cell cycle synchronization and timed delivery of Cas9 ribonucleoprotein complexes.

Forward genetic screening has provided insight into the molecular mechanisms and stress pathways that promote tumor cell recognition by natural killer cells.

Nucleosomes provide a direct and profound block to the activity of the CRISPR effector protein Cas9, suggesting future sophisticated design rules for CRISPR targeting.

An EASAC working group on genome editing recommends that regulators should focus on specific applications of these new techniques rather than attempting to regulate genome editing itself as a new technology.

The guide RNA and donor DNA of the CRISPR/Cas system tolerate large chemical modifications and can be engineered for enhanced delivery and gene editing.

The CRISPR/Cas9 system can be used with recombinant AAV6 donor delivery to facilitate simultaneous, targeted integration into multiple genetic loci in hematopoietic stem and progrenitor cells.

Live real time imaging and perturbation experiments reveal how vimentin integrates with early damage induced reactive oxygen species to mediate collagen rearrangements and epithelial cell projections during wound repair and regeneration.

Divergent Cas9 enzymes direct site-specific single-stranded RNA cleavage, reducing infection by RNA phage in vivo and enabling programmable, PAM-independent repression of gene expression in bacteria.

Cancer cells can grow in vitro and in vivo in the absence of maternal embryonic leucine zipper kinase (MELK).

Estrogen is a systemic factor that promotes hematopoietic regeneration by activating the unfolded protein responses.